Effects of artesunate on cytokinesis and G2/M cell cycle progression of tumour cells and budding yeast

Cancer Genomics and Proteomics

Volumn 7, Issue 6, 2010, Pages 337-346

  Steinbrück, Lisa ^a   Pereira, Gislene ^a   Efferth, Thomas ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Anticancer activity; Artemisinin; Cell cycle arrest; Cytokinesis; Mitotic checkpoint genes

Indexed keywords

ARTESUNATE; BUB1 RELATED PROTEIN; BUB2 RELATED PROTEIN; BUB3 RELATED PROTEIN; PROTEIN MAD1; PROTEIN MAD2; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CENTROSOME; CYTOKINESIS; CYTOTOXICITY; DRUG EFFECT; FLOW CYTOMETRY; GENE DELETION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MITOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; SACCHAROMYCES CEREVISIAE; TUMOR CELL; YEAST CELL;

ARTESUNATE; MAMMALIA; SACCHAROMYCES CEREVISIAE; SACCHAROMYCETALES;

EID: 78650944133     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Cragg GM, Newman DJ and Yang SS: Natural product extracts of plant and marine origin having antileukemia potential. The NCI experience. J Nat Prod 69: 488-498, 2006.
2. Boik J: Natural compounds in cancer therapy. Oregon Medical Press, 2001.
3. Yeung S, Pongtavornpinyo W, Hastings IM, Mills AJ and White NJ: Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. Am J Trop Med Hyg 71: 179-186, 2004.
4. Efferth T: Mechanistic perspectives for 1,2,4-trioxanes in anticancer therapy. Drug Resist Updat 8: 85-97, 2005.
5. Merali S and Meshnick SR: Susceptibility of Pneumocystis carinii to artemisinin in vitro. Antimicrob Agents Chemother 35: 1225-1227, 1991.
6. Ke OY, Krug EC, Marr JJ and Berens RL: Inhibition of growth of Toxoplasma gondii by qinghaosu and derivatives. Antimicrob Agents Chemother 34: 1961-1965, 1990.
7. Romero MR, Efferth T, Serrano MA, Castano B, Macias RI, Briz O and Marin JJ: Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an 'in vitro' replicative system. Antiviral Res 68: 75-83, 2005.
8. Efferth T, Marschall M, Wang X, Huong SM, Hauber I, Olbrich A, Kronschnabl M, Stamminger T and Huang ES: Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. J Mol Med 80: 233-242, 2002.
9. Ribeiro IR and Olliaro P: Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials. Med Trop (Mars) 58: 50-53, 1998.
10. Efferth T and Kaina B: Toxicity of the antimalarial artemisinin and its derivatives. Crit Rev Toxicol 40: 405-421, 2010.
11. Woerdenbag HJ, Moskal TA, Pras N, Malingre TM, el-Feraly FS, Kampinga HH and Konings AW: Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells. J Nat Prod 56: 849-856, 1993.
12. Zheng GQ: Cytotoxic terpenoids and flavonoids from Artemisia annua. Planta Med 60: 54-57, 1994.
13. Lai H and Singh NP: Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett 91: 41-46, 1995.
14. Efferth T, Rücker G, Falkenberg M, Manns D, Olbrich A, Fabry U and Osieka R: Detection of apoptosis in KG-1a leukemic cells treated with investigational drugs. Arzneimittelforschung 46: 196-200, 1996. (Pubitemid 26079152)
15. Efferth T, Dunstan H, Sauerbrey A, Miyachi H and Chitambar CR: The anti-malarial artesunate is also active against cancer. Int J Oncol 18: 767-773, 2001.
16. Berger TG, Dieckmann D, Efferth T, Schultz ES, Funk JO, Baur A and Schuler G: Artesunate in the treatment of metastatic uveal melanoma first experiences. Oncol Rep 14: 1599-1603, 2005.
17. Golenser J, Waknine JH, Krugliak M, Hunt NH and Grau GE: Current perspectives on the mechanism of action of artemisinins. Int J Parasitol 36: 1427-1441, 2006.
18. Efferth T: Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr Drug Targets 7: 407-421, 2006.
19. Meshnick SR: The mode of action of antimalarial endoperoxides. Trans R Soc Trop Med Hyg 88(Suppl 1): S31-S32, 1994.
20. Efferth T, Giaisi M, Merling A, Krammer PH and Li-Weber M: Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. PLoS ONE 2: e693, 2007.
21. Shterman N, Kupfer B and Moroz C: Comparison of transferrin receptors, iron content and isoferritin profile in normal and malignant human breast cell lines. Pathobiology 59: 19-25, 1991.
22. Efferth T, Benakis A, Romero MR, Tomicic M, Rauh R, Steinbach D, Hafer R, Stamminger T, Oesch F, Kaina B and Marschall M: Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med 37: 998-1009, 2004.
23. Kelter G, Steinbach D, Konkimalla VB, Tahara T, Taketani S, Fiebig HH and Efferth T: Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumor cells towards artesunate. PLoS ONE 2: e798, 2007.
24. Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, Weber HO, Hengstler JG, Halatsch ME, Volm M, Tew KD, Ross DD and Funk JO: Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol 64: 382-294, 2003.
25. Li PC, Lam E, Roos WP, Zdzienicka MZ, Kaina B and Efferth T: Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Res 68: 4347-4351, 2008.
26. Li LN, Zhang HD, Yuan SJ, Tian ZY, Wang L and Sun ZX: Artesunate attenuates the growth of human colorectal carcinoma and inhibits hyperactive Wnt/beta-catenin pathway. Int J Cancer 121: 1360-1365, 2007.
27. Konkimalla VB, Blunder M, Korn B, Soomro SA, Jansen H, Chang W, Posner GH, Bauer R and Efferth T: Effect of artemisinins and other endoperoxides on nitric oxide-related signaling pathway in RAW 264.7 mouse macrophage cells. Nitric Oxide 19: 184-191, 2008.
28. Dell'Eva R, Pfeffer U, Vene R, Anfosso L, Forlani A, Albini A and Efferth T: Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem Pharmacol 68: 2359-2366, 2004. (Pubitemid 39535108)
29. Zhou HJ, Wang WQ, Wu GD, Lee J and Li A: Artesunate inhibits angiogenesis and down-regulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells. Vascul Pharmacol 47: 131-138, 2007.
30. Bommer UA and Thiele BJ: The translationally controlled tumour protein (TCTP). Int J Biochem Cell Biol 36: 379-385, 2004.
31. Gachet Y, Reyes C, Goldstone S and Tournier S: The fission yeast spindle orientation checkpoint: a model that generates tension? Yeast 23: 1015-1029, 2006.
32. Yarm FR: Plk phosphorylation regulates the microtubule-stabilizing protein TCTP. Mol Cell Biol 22: 6209-6221, 2002.
33. Jiao Y, Ge CM, Meng QH, Cao JP, Tong J and Fan SJ: Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. Acta Pharmacol Sin 28: 1045-1056, 2007.
34. Diaz-Martinez LA and Yu H: Running on a treadmill: dynamic inhibition of APC/C by spindle checkpoint. Cell Div 2: 23, 2007.
35. Stryer L, Berg JM, Tymoczko JL and Clarke NG: Biochemistry. W.H. Freeman and Co, 2002.
36. Janke C, Magiera MM, Rathfelder N, Taxis C, Reber S, Maekawa H, Moreno-Borchart A, Doenges G, Schwob E, Schiebel E and Knop M: A versatile toolbox for PCR-based tagging of yeast genes: new fluorescent proteins, more markers and promoter substitution cassettes. Yeast 21: 947-962, 2004.
37. Caydasi AK and Pereira G: Spindle alignment regulates the dynamic association of checkpoint proteins with yeast spindle pole bodies. Dev Cell 16: 146-156, 2009.
38. Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, Park J, Scherf U, Lee JK, Reinhold WO, Weinstein JN, Mesirov JP, Lander ES and Golub TR: Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 98: 10787-10792, 2001.
39. Hou J, Wang D, Zhang R and Wang H: Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res 14: 5519-5530, 2008.
40. Sundar SN, Marconett CN, Doan VB, Willoughby JA Sr. and Firestone GL: Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells. Carcinogenesis 29: 2252-2258, 2008.
41. Willoughby JA Sr, Sundar SN, Cheung M, Tin AS, Modiano J and Firestone GL: Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. J Biol Chem 284: 2203-2213, 2009.
42. Kramer A, Neben K and Ho AD: Centrosome aberrations in hematological malignancies. Cell Biol Int 29: 375-383, 2005.
43. Fukasawa K: Centrosome amplification, chromosome instability and cancer development. Cancer Lett 230: 6-19, 2005.
44. Uetake Y and Sluder G: Cell cycle progression after cleavage failure: mammalian somatic cells do not possess a 'tetraploidy checkpoint'. J Cell Biol 165: 609-615, 2004.
45. Knutsen T, Gobu V, Knaus R, Padilla-Nash H, Augustus M, Strausberg RL, Kirsch IR, Sirotkin K and Ried T: The interactive online SKY/M-FISH & CGH database and the Entrez cancer chromosomes search database: linkage of chromosomal aberrations with the genome sequence. Genes Chromosomes Cancer 44: 52-64, 2005.
46. Lens SM, Wolthuis RM, Klompmaker R, Kauw J, Agami R, Brummelkamp T, Kops G and Medema RH: Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J 22: 2934-2947, 2003.
47. Ruchaud S, Carmena M and Earnshaw WC: Chromosomal passengers: conducting cell division. Nat Rev Mol Cell Biol 8: 798-812, 2007.
48. Vader G, Kauw JJ, Medema RH and Lens SM: Survivin mediates targeting of the chromosomal passenger complex to the centromere and midbody. EMBO Rep 7: 85-92, 2006.
49. Sandall S, Severin F, McLeod IX, Yates JR 3rd, Oegema K, Hyman A and Desai A: A Bir1-Sli15 complex connects centromeres to microtubules and is required to sense kinetochore tension. Cell 127: 1179-1191, 2006.
50. Carvalho A, Carmena M, Sambade C, Earnshaw WC and Wheatley SP: Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci 116(Pt 14): 2987-2998, 2003.
51. Honda R, Korner R and Nigg EA: Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell 14: 3325-3341, 2003.
52. Morrow CJ, Tighe A, Johnson VL, Scott MI, Ditchfield C and Taylor SS: Bub1 and aurora B cooperate to maintain BubR1-mediated inhibition of APC/CCdc20. J Cell Sci 118: 3639-3652, 2005.
53. D'Avino PP, Savoian MS and Glover DM: Cleavage furrow formation and ingression during animal cytokinesis: a microtubule legacy. J Cell Sci 118: 1549-1558, 2005.
54. Barr FA, Sillje HH and Nigg EA: Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 5: 429-440, 2004.
55. Lane HA and Nigg EA: Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk 1) in the functional maturation of mitotic centrosomes. J Cell Biol 135: 1701-1713, 1996.
56. Mager WH and Winderickx J: Yeast as a model for medical and medicinal research. Trends Pharmacol Sci 26: 265-273, 2005.
57. Musacchio A and Hardwick KG: The spindle checkpoint: structural insights into dynamic signalling. Nat Rev Mol Cell Biol 3: 731-741, 2001.
58. Larsen NA, Al-Bassam J, Wei RR and Harrison SC: Structural analysis of Bub3 interactions in the mitotic spindle checkpoint. Proc Natl Acad Sci USA 104: 1201-1206, 2007. (Pubitemid 46183982)